Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years.

In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had multiple products that generated over $1 billion in revenue, including its ...

If any pharmaceutical producer is going to exploit the full potential of such medications, it's the well-capitalized Eli Lilly. I would even consider it to be a leading healthcare stock ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

29,097 people played the daily Crossword recently. Can you solve it faster than others?29,097 people played the daily Crossword recently. Can you solve it faster than others?

See the 10 stocks » Is this a sign the stock is in trouble and likely headed for more of a decline this year? Or could now be a good time to buy Eli Lilly on the dip? On Jan. 14, Eli Lilly ...

Fears of heightened oversight in the industry could weigh on not just Eli Lilly, but healthcare stocks as a whole. Plus, there is also the concern that the stock's high valuation may finally be ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...